Literature DB >> 3257242

Autoimmune MRL/lpr mice sera contain IgG with interleukin 3-like activity.

Y Ohta1, S Tamura, E Tezuka, M Sugawara, S Imai, H Tanaka.   

Abstract

The spleen cells, thymocytes, and bone marrow cells of autoimmune MRL/MP-lpr/lpr (MRL/lpr) mice do not constitutively produce interleukin 3 (IL-3), but these mice had IL-3-like activity in their sera. MRL/lpr sera supported the growth of the IL-3-dependent cell lines FDC-P2 and DA-1 but not the growth of IL-2-dependent T-572 cells. This IL-3-like activity increased with age. Biochemical analysis of the MRL/lpr sera by anion-exchange chromatography, gel filtration on a Superose 12 column, the binding to protein-A and sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that the serum factor with the IL-3-like activity was not IL-3 itself but was associated with IgG. Flow cytometric analysis also showed that the serum level of the Ig capable of binding FDC-P2 cells was high in MRL/lpr but not in MRL/+ mice. We suggest that IL-3 is not responsible for lymphoid hyperplasia, contrary to a previous report; rather auto-antibodies directed toward the IL-3 receptor may act pathogenically in MRL/lpr mice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257242

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Voltage-gated K+ channels in the mouse interleukin 3-dependent cell line, FDC-P2.

Authors:  H Tanaka; Y Ohta; T Sugimoto; Y Kurachi
Journal:  J Membr Biol       Date:  1991-03       Impact factor: 1.843

Review 2.  Effects of leflunomide on immune responses and models of inflammation.

Authors:  R R Bartlett; H Anagnostopulos; T Zielinski; T Mattar; R Schleyerbach
Journal:  Springer Semin Immunopathol       Date:  1993

3.  IL-3 contributes to development of lupus nephritis in MRL/lpr mice.

Authors:  Kerstin Renner; Fabian Johannes Hermann; Kathrin Schmidbauer; Yvonne Talke; Manuel Rodriguez Gomez; Gabriela Schiechl; Jens Schlossmann; Hilke Brühl; Hans-Joachim Anders; Matthias Mack
Journal:  Kidney Int       Date:  2015-07-01       Impact factor: 10.612

4.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

5.  CD3+ T cells in severe combined immunodeficiency (scid) mice. VI. Rescue of scid-derived, IgM-producing B cells by transfer of CD4+ CD8- T cells from various lymphoid organs.

Authors:  A Rudolphi; M H Claesson; J Reimann
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.